Feed
Read More
I see that shares of $HIMS have fallen more than 60% from their all-time highs (ATH), which is no small amount. I personally don't follow this company closely right now, but I'd be interested to know the main reasons for this decline.
Does anyone have any idea why $HIMS shares have dropped so significantly? Do you see it more as an opportunity or as a trap?
Read More
📅 This week's key market events!
Earnings season continues, especially in the technology and pharmaceutical sectors. Added to this are macro data that may stir market expectations for the next rate hike. Here's a round-up of the highlights:
🔵 Monday
Results before the markets open:
OnSemiconductor $ON - need to watch demand for chips in the automotive sector
Tyson Foods $TSN - price...
Read more
Zobrazit další komentáře
Read More
💊 Novo Nordisk expands distribution of Wegova via telehealth. Hims & Hers shares jumped by more than 25%!
Danish pharmaceutical giant Novo Nordisk $NVO is coming up with another move to accelerate sales of its weight loss drug Wegova. The drug will now also be available through telemedicine platforms such as Hims & Hers Health $HIMS, LifeMD, and including NovoCare's direct...
Read more
Zobrazit další komentáře
Unfortunately,$NVO is still falling, but it creates a nice opportunity to establish a position.
Read More
📉 Hims & Hers shares fall by more than 20%!
Shares of Hims & Hers Health $HIMS plummeted by more than 30 %, even though the company reported year-over-year revenue growth of 95 % to $481 million, beating Wall Street' s expectations . Important, however, were weaker gross margins and news that the company will likely discontinue sales of compounded semaglutide (a diabetes drug),...
Read more
Zobrazit další komentáře
$HIMS was very overpriced for a long time, but now after the drop it's better and the price is starting to look quite interesting.
Read More
📅 This week's key events: Corporate results, macro data and tech dominance !📊
The new week brings earnings season in full swing, along with important economic indicators. Personally, I'll be focusing on the results Nvidia, Dell, HP a Salesforcewhile macro data like GDP per Q4 and data on PCE inflation will certainly be key to future market direction.
🍕Monday
Results before the...
Read more
Zobrazit další komentáře
We'll see how the $NVDA results come out tomorrow and how other stocks react.
Read More
Hims & Hers Health: growth title in telemedicine with explosive revenue growth
Hims & Hers Health $HIMS is one of the fastest-growing stocks of 2024, with its expansion into the weight-loss injections (GLP-1) segment and aggressive marketing strategy driving its stock up 150%.
1. Rocketing revenue growth
- Q1: +46% | Q2: +52% | Q3: +72%
- Expected growth for Q4: up to 90%
-Demand...
Read more
Read More
Hims & Hers Health : A fast-growing healthcare company
Hims & Hers Health $HIMS is an innovative player in telemedicine and health products. It offers consumers subscription-based services that provide easy access to prescriptions and other health and wellness products. Users can complete virtual visits with physicians of various specialties and obtain needed prescriptions...
Read more
Zobrazit další komentáře
In terms of numbers jw it's a solid company. Looking at the chart, there's a big drop ahead. I don't dare to guess where it will go.
Read More
📆 Next week's investment calendar! 🚀
Here's my recap of the most interesting events coming up in the next week!
Monday 🌐:
📊 New Home Sales for January (Expectations 684,000, previously 664,000), month-over-month for January (expected +3%, previously +8%).
💹 Earnings: Domino's Pizza $DPZ, Freshpet $FRPT, Hims & Hers $HIMS, Unity Software $U, Workday $WDAY, Zoom $ZM and other...
Read more
I own some and I'm considering buying more. They have excellent results, the market is large, and they've even started international expansion in telehealth. The market may be wondering whether that rapid growth is sustainable. And in the US everyone is probably nervous about Trump's interference in this segment. They'll likely be sparring again with the big US market player, company $NVO, over the weight-loss drug they devised themselves, with Wegovy as their benchmark. It probably isn't for someone who doesn't like big swings, but their business model is hard to deny.